Pressure BioSciences, Inc. · OTC:PBIO

Pressure BioSciences — WallStreet Research (August 2014)

26 slides from Pressure BioSciences's conference presentation, Aug 25, 2014

  1. Slide 1: Investor Presentation: Pressure BioSciences, Inc.

    Investor Presentation Pressure BioSciences, Inc. (OTCQB: PBIO) Discovery Starts with Sample Preparation™ WallStreet Research August 19 & 20, 2014 Richard T. Schumacher PB ji President, CEO, Board Member

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation may contain forward looking statements that reflect management's current views and opinions as to the status of the Company's products, technology and other future events and operations. These statements are neither a promise nor guarantee, but involve ri

  3. Slide 3: Company Overview

    Company Overview + OTCQB: PBIO + Nine (9) FT Employees; Strong Mgmt Team and Board of Directors + 24 Patents: Pressure Cycling Technology (PCT) Platform + ~32M Common Shares/CS Equivalents OS (Float ~12M) + Market Cap (fully diluted): $11.2 Million + Development and Sale of PCT-based Products (Instr

  4. Slide 4: Experienced Senior Management & Board

    Experienced Senior Management & Board Management + Mr. Richard T. Schumacher, President & CEO Boston Biomedica (CEO, Founder); Panacos Pharma (President, Co-founder); Trinity Biotech (Founding Group); CBR Labs (Gen’ | Mgr) - Harvard Medical School + Dr. Edmund Y. Ting, Senior Vice President of Engin

  5. Slide 5: What is a Biomarker?

    What is a Biomarke: Molecules (e.g., genes, proteins, lipids) found in tissue (e.g., cells) or body fluids (e.g., blood) that correlate — directly or indirectly — with the presence or absence, the progression or recurrence, and the effects of treatment on a disease or a disorder. Identify Disease Bi

  6. Slide 6: Estimated Market: Biomarker Discovery

    'stimated Market: Biomarker Discovery R&D Services Biomarker Discovery Pharmaceuti- Biotechnology 3 R&D “Biomarker Validation Sopice eags Sees. Academic and WW Biomarker Market Est. to Reach $25.79B, by 2016 - 2012 ASDReports Diagnostics Near Patent Care S Emergency Room tpoe Diagnostics b meats or

  7. Slide 7: Value Proposition: PCT-based biological sample preparation

    Value Proposition: PCT-based biological sample preparation + Analysis of DNA, RNA, Proteins, & Lipids (“biomolecules”) is Crucial to the Discovery of New Biomarkers + The Quality of Biomolecule Analysis Depends Significantly on the Quality of the Preparation of the Sample to be Analyzed + Biological

  8. Slide 8: Sample Preparation

    Sample Preparation Sample preparation is a term that refers to a wide range of activities that precede virtually all forms of scientific analysis. Sample preparation is often complex, time- consuming, and one of the most error-prone steps of scientific research. It is none-the-less a ubiquitous labo

  9. Slide 9: Sample Preparation for Cell Lysis

    ary Sample Preparation for Cell Lysis

  10. Slide 10: Tools for Discovery

    ols for Discovery 500,000 Scientists in 80,000 Biological Research Labs WW Assortment of Analytical Instruments Used in the Discovery Process, e.g., + HPLC (est. of over 230,000 systems currently in use) + Mass Spectrometers (est. of over 16,000 MS labs WW) + DNA Sequencers, Real Time PCR + Electrop

  11. Slide 11: Sample Input Quality = Sample Result Quality

    Sample Input Quality = Sample Result Quality Scientific research can be broken down to three key elements: sample preparation, analysis, & data reduction/interpretation PBI “Discovery Starts with Sample Preparation” "

  12. Slide 12: Biomarker/Forensics Sample Prep Market: Estimated Size

    Biomarker/Forensics Sample Prep Market: Estimated Size + Genomics (DNA/RNA) Market to Reach $7.1B in 2015 > + Next Generation Sequencing (DNA) Market to Reach $2.7B in 2017¢ + Mass Spectrometry Market (Proteins/Lipids) at $2.7B in 2011 and Predicted to Increase at a CAGR of 7.83 Percent for 2011-201

  13. Slide 13: Competitive Landscape

    Competitive Landscape Nearly All Competitive Methods Involve Mechanical Disruption Mortar & Pestle Dounce homogenizer (glass on glass) Potter-Elvenhjem homogenizer (Teflon on glass) Enzymatic Digestion Polytron shearing homogenizers Blenders Bead Beating Sonication Repeated Freeze/Thaw cycles French

  14. Slide 14: PCT Sample Preparation System

    PCT Sample Preparation System — Em Barocycler™ NEP2320 Barocycler™ NEP3229 PCT-dependent Kits PBI MicroTubes 4

  15. Slide 15: Selected Marquee Customers (40 of 150)

    Selected Marquee Customers (40 of 150) Amgen Biogen Lilly Novartis Monsanto BM Squibb Merck Centocor Takeda Pharmaceuticals Momenta Pharmaceuticals US Army FBI Food and Drug Administration US Department of Agriculture National Institutes of Health Armed Forces Inst. of Pathology Centers for Disease

  16. Slide 16: PCT Focus Area: Biomarker Discovery & Forensics

    PCT Focus Area: Biomarker Discovery & Forensics Biomarker Discovery: Cancer, Heart Disease, Stroke, Inf. Diseases, Etc. Dr. Andreas Huhmer — Thermo Fisher Scientific advantages of speed and quality using PCT in mass spec workflow Dr. Michael Alterman — Tumor Vaccines and Biotechnology Branch, CBER,

  17. Slide 17: PCT Focus Area: Biomarker Discovery & Forensics

    PCT Focus Area: Biomarker Discovery & Forensics Forensics Dr. Bruce Budowle, Health Science Center, University of North Texas improved detection of DNA in forensic samples using PCT Dr. Bruce McCord, Florida International University improved processing of forensic (rape kit) samples using PCT Dr. Pa

  18. Slide 18: The Problem

    The Problem Automated liquid handling helps ensure accuracy and reproducibility, eliminates repetitive tasks, and frees personnel for other activities. |Manual Automated 18

  19. Slide 19: The Solution (4 years in the making)

    e Solution (4 years in the maki + Initial Application: High pressure digestion + Consumable: — Proprietary 8-well strips + Number of Samples: — 48 samples + User Control: — Easy to use touch screen LabView Software 19

  20. Slide 20: Barozyme HT48: High Throughput PCT Processing

    Barozyme HT48: High Throughput PCT Processing Planned Release - June 16, 2014

  21. Slide 21: Initial (Jan 2015) Commercial Application: Barozyme HT48

    Initial (Jan 2015) Commercial Application: Barozyme HT48 Biomarker Discovery (Enhanced Mass Spectrometry Sample Preparation) We Believe: + there are approx 16,000 MS labs worldwide (8,000 U.S.); approx 50% do protein analysis + most MS protein analyses require extraction then digestion of proteins p

  22. Slide 22: Initial (Jan 2016) Commercial Application: Barozyme HT48

    Initial (Jan 2016) Commercial Application: Barozyme HT48 PBI Forensics (Enhanced Rape Kit Sample Preparation) We Believe: there is a backlog of ~400,000 untested Rape Kits in the U.S. & ~ 300,000 new rapes/year + because of the high cost and complexity of rape kit testing, the backlog continues to g

  23. Slide 23: Key Investment Highlights

    Key Investment Highlights PBI Pressure Cycling Technology (PCT): Powerful, Enabling, Patented with Significant Advantages Over Competitive Methods Proven Technology: ~ 250 Installations in ~150 Marquee Laboratories Attractive “Razor/Razorblade” Business Model Experienced Management Team and Board of

  24. Slide 24: Professor Wayne L. Hubbell

    Professor Wayne L. Hubbell + Distinguished Professor of Biochemistry: UCLA School of Medicine Assoc. Dir.: Jules Stein Eye Institute (UCLA) Member, National Academy of Sciences Fellow, American Academy of Arts and Sciences Member, UCLA Molecular Biology Institute & UCLA Brain Research Institute Gold

  25. Slide 25: Professor Jennifer Van Eyk

    Professor Jennifer Van Eyk + Professor of Medicine, Cedars-Sinai Med. Ctr. Director, Basic Science Research, the Barbara Streisand Women’s HC Director, Adv Clinical Biosystems Rsh. Institute’ Director, NHLBI Prot Innov Ctr, Heart Failure Formerly Professor of Medicine, Johns Hopkins School of Medici

  26. Slide 26: Mr. David Weild IV

    Mr. David Weild IV + Founder, Chairman, and CEO, IssuWorks CEO, Weild & Co Holdings (Inv Banking Firm) Former Vice-Chairman of NASDAQ + Former Head of Global Equity Transactions, Prudential Securities Former President, PrudentialSecurities.com + Former Head, Capital Markets Group of Grant Thornton L

Pressure Biosciences — WallStreet Research (August 2014) on 6ix